Preview Mode Links will not work in preview mode
Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show offers a glimpse into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the evolving dynamics in the medical and healthcare landscape. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations often focus on how technology is empowering providers, care facilities, pharmaceutical companies, and payers to improve patient outcomes and reduce friction across the healthcare landscape.  Popular Topics Include: Virtual and digital health Use of AI, ML, and robots for clinical and administrative purposes  Value-based healthcare  Precision and stratified medicine Next-generation immuno, cell, and gene therapies Vaccines for infectious diseases and oncology Biomarkers and diagnostics Rare diseases MedTech and medical devices Clinical trials  Population health Chronic conditions l Clinician and staff burnout Smart hospitals The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.

Jul 27, 2023

Jennifer Jones-McMeans, Divisional Vice President of Global Clinical Affairs at Abbott, discusses Abbot's new diversity initiative to help address mistrust and societal barriers that underrepresented populations face in receiving healthcare and participating in clinical trials. Through partnerships, clinical research coordinators from diverse backgrounds working in smaller institutions are trained to work with these populations. Norton Health with the Institute for Health Equity is putting funding and infrastructure in place to build a research program model for historically Black colleges and universities to attract more diverse participation in trials and build more vital research institutions.     

Jennifer explains, "I had a good conversation with a physician today from the New York area, and we talked about one barrier that is translation. We discussed that the clinical trial this individual is working on did not have the resources for translation services. And so, if you think about something as simple as that, it means that patients who are non-English speaking, their family members, and researchers cannot even approach them because they may not have the translated material. That's one very simple barrier. We can go back to also time - patient time is critical. If you think about individuals who are working and who have family obligations, how do we actually reduce the barrier of time?"

"Well, this is where when we think about race and ethnicity, race is not biologic. Remember, it's a social construct. Ethnicity is a social construct. Yes, if you look geographically, we're 99.9% similar when it comes to human genomes. Who I am as an African-American female, I may have far more genetic similarities to someone who is not of African descent. We first have to dispel that. Yes, there can be genetic elements. We do know that geographically you may see a higher frequency of certain genetic associations and whatnot. But I think it becomes less about this because genetics and race are not biologic."  

"When you think about who do I need to include? You have to bring in this whole concept of social determinants of health, or also concepts where people, cultures, groups, individuals are impressed not only by the biology but what their surroundings are." 

 #Abbott #ClinicalTrials #DiversityinClinicalTrials #DiversityResearch #Healthcare #SDOH #SocialDeterminantsofHealth 

Abbott.com

Download the transcript here

Abbott